Patients with HER2-mutated CRC also have KRAS mutations, which suggests that concomitant HER2 and KRAS mutations may promote colorectal tumorigenesis, and these patients exhibit little response to EGFR-targeted therapy [26–29]. Here, KRAS is linked to colorectal carcinoma.